



RECEIVED 1635

JUN 05 2001

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on:

Date: 5/29/01 By: Deborah Dietzmeier

TECH CENTER 1600/2900

DOCKET No.: 0450-0031.30

#17 / K.T.
6/5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Bartelmez *et al.*

SERIAL NO.: 09/684,061

FILED: October 6, 2000

FOR: ANTISENSE COMPOSITIONS AND CANCER-TREATMENT METHODS

EXAMINER: Zara, J.

ART UNIT: 1635

ELECTION

Response to Restriction Requirement

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action mailed April 27, 2001, please amend the application as follows.

REMARKS

I. Invention Groups Proposed by the Examiner

Claims 1-20 are pending for prosecution in the case.

The Examiner states that Claims 2, 6, 11 and 15 are drawn to nucleotide sequences, nucleotide constructs and/or methods requiring the use of nucleotide sequences or constructs that contain more than one individual, independent and distinct nucleotide sequence in alternative form.

The Examiner has not divided the claims into particular groups, but states that Applicants are required to select no more than one of the individual sequences recited in the claims for examination.

II. Election of Invention Group

In order to make a substantive response to the Office Action mailed April 27, 2001, Applicants make a provisional election of the sequence presented as SEQ ID NO:1, with traverse.